Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263010 · ClinicalTrials.gov registry record · Phase 1
Allopregnanolone as a Regenerative Treatment for Parkinson's Disease
A Phase 1 study, sponsored by Roberta Brinton.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06263010: Completed Phase 1 study, sponsored by Roberta Brinton.
NCT06263010 is a Phase 1 study that has completed, run by Roberta Brinton. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06263010, a Phase 1 study, has completed, sponsored by Roberta Brinton.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.
Primary Outcome
Proportion of participant progression to study completion.
Interventions
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2025-07-15 |
| Phase | Phase 1 |
What the finished NCT06263010 record still lists
NCT06263010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Allopregnanolone is the first listed.
NCT06263010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06263010 about?
NCT06263010 is a clinical study titled "Allopregnanolone as a Regenerative Treatment for Parkinson's Disease". The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is all...
What is the current status of trial NCT06263010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-01-12. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT06263010?
The interventions under investigation include: Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT06263010?
This trial is sponsored by Roberta Brinton, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06263010's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI